Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer

被引:2
作者
Boldrini, L
Faviana, P
Gisfredi, S
Di Quirico, D
Lucchi, M
Mussi, A
Angeletti, CA
Baldinotti, F
Fogli, A
Simi, P
Basolo, F
Pingitore, F
Fontanini, G
机构
[1] Univ Pisa, Dept Oncol Transplants & Adv Technol Med, I-56100 Pisa, Italy
[2] Univ Pisa, Dept Cardiothorac Surg, I-56100 Pisa, Italy
[3] UO Cytogenet & Mol Genet, Dept Oncol, I-56100 Pisa, Italy
关键词
NSCLC; Fas (APO-1/CD95); p53; mutations;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fas (APO-1/CD95) is a broadly expressed death receptor involved in a series of physiological and pathological apoptotic processes. One of the possible mechanisms for resistance to apoptosis signaling in the immune system as well as in the pathogenesis of non-lymphoid malignancies is the presence of Fas mutations within the entire gene. We investigated, in 79 non-small cell lung cancer (NSCLC) samples, the promoter and the entire coding region of the Fas gene by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing in order to detect putative alterations. Sixteen of 79 tumor samples (20.2%) were found to have Fas alterations, either in promoter or exon region. Since the loss of Fas apoptotic function might be linked to p53 alterations, which are often involved in the development of NSCLC, we analyzed p53 status in 40 of the 79 NSCLC samples. p53 mutations were found to be more frequently present than Fas gene alterations (25 out of 40 cases, 62.5%). These data increase the knowledge regarding mutations of apoptosis-genes involved in the pathogenesis of NSCLC, and give benefits for the clinical management of this type of tumor.
引用
收藏
页码:155 / 159
页数:5
相关论文
共 13 条
[1]  
Beltinger C, 1998, BLOOD, V91, P3943
[2]   Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis [J].
Bennett, M ;
Macdonald, K ;
Chan, SW ;
Luzio, JP ;
Simari, R ;
Weissberg, P .
SCIENCE, 1998, 282 (5387) :290-293
[3]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[4]   Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells [J].
Fukazawa, T ;
Fujiwara, T ;
Morimoto, Y ;
Shao, J ;
Nishizaki, M ;
Kadowaki, Y ;
Hizuta, A ;
Owen-Schaub, LB ;
Roth, JA ;
Tanaka, N .
ONCOGENE, 1999, 18 (13) :2189-2199
[5]  
GREENBLATT MS, 1994, CANCER RES, V54, P4855
[6]   The 1995 Walter Hubert lecture - Molecular epidemiology of human cancer: Insights from the mutational analysis of the p53 tumour-suppressor gene [J].
Harris, CC .
BRITISH JOURNAL OF CANCER, 1996, 73 (03) :261-269
[7]   Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer [J].
Lee, SH ;
Shin, MS ;
Park, WS ;
Kim, SY ;
Kim, HS ;
Han, JY ;
Park, GS ;
Dong, SM ;
Pi, JH ;
Kim, CS ;
Kim, SH ;
Lee, JY ;
Yoo, NJ .
ONCOGENE, 1999, 18 (25) :3754-3760
[8]  
Lehman T A, 1994, IARC Sci Publ, P399
[9]   p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs [J].
Müller, M ;
Wilder, S ;
Bannasch, D ;
Israeli, D ;
Lehlbach, K ;
Li-Weber, M ;
Friedman, SL ;
Galle, PR ;
Stremmel, W ;
Oren, M ;
Krammer, PH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (11) :2033-2045
[10]   EXPRESSION OF THE FAS ANTIGEN ON PRIMARY HUMAN LEUKEMIA-CELLS [J].
MUNKER, R ;
LUBBERT, M ;
YONEHARA, S ;
TUCHNITZ, A ;
MERTELSMANN, R ;
WILMANNS, W .
ANNALS OF HEMATOLOGY, 1995, 70 (01) :15-17